EP1307204A4 - PROTEASES INHIBITORS - Google Patents
PROTEASES INHIBITORSInfo
- Publication number
- EP1307204A4 EP1307204A4 EP01946344A EP01946344A EP1307204A4 EP 1307204 A4 EP1307204 A4 EP 1307204A4 EP 01946344 A EP01946344 A EP 01946344A EP 01946344 A EP01946344 A EP 01946344A EP 1307204 A4 EP1307204 A4 EP 1307204A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- protease inhibitors
- protease
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59384500A | 2000-06-14 | 2000-06-14 | |
US593845 | 2000-06-14 | ||
PCT/US2001/019062 WO2001095911A1 (en) | 2000-06-14 | 2001-06-14 | Protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1307204A1 EP1307204A1 (en) | 2003-05-07 |
EP1307204A4 true EP1307204A4 (en) | 2004-06-02 |
Family
ID=24376433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01946344A Withdrawn EP1307204A4 (en) | 2000-06-14 | 2001-06-14 | PROTEASES INHIBITORS |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1307204A4 (es) |
JP (1) | JP2004503502A (es) |
KR (1) | KR20030008220A (es) |
CN (1) | CN1444481A (es) |
AP (1) | AP2002002671A0 (es) |
AR (1) | AR032622A1 (es) |
AU (1) | AU2001268407A1 (es) |
BG (1) | BG107327A (es) |
BR (1) | BR0111693A (es) |
CA (1) | CA2412353A1 (es) |
CZ (1) | CZ20024086A3 (es) |
EA (1) | EA200300018A1 (es) |
EC (1) | ECSP024388A (es) |
HU (1) | HUP0301231A2 (es) |
IL (1) | IL153421A0 (es) |
MA (1) | MA25758A1 (es) |
MX (1) | MXPA02012442A (es) |
NO (1) | NO20025786L (es) |
NZ (1) | NZ522965A (es) |
OA (1) | OA12288A (es) |
PE (1) | PE20011374A1 (es) |
PL (1) | PL360508A1 (es) |
SK (1) | SK17592002A3 (es) |
WO (1) | WO2001095911A1 (es) |
ZA (1) | ZA200209808B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
EP1231922A4 (en) * | 1999-11-10 | 2004-06-23 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
EP1392657A4 (en) * | 2000-11-22 | 2004-03-10 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
PT1370260E (pt) | 2001-02-20 | 2011-02-01 | Chugai Pharmaceutical Co Ltd | Azóis como inibidores da malonil-coa-descarboxilase úteis como moduladores metabólicos |
EP1401453A4 (en) * | 2001-05-17 | 2005-04-06 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
ES2314491T3 (es) | 2003-08-01 | 2009-03-16 | Chugai Seiyaku Kabushiki Kaisha | Compuestos azol basados en cianoguanidina utiles como inhibidores de la manonil-coa descaraboxilasa. |
CA2533747C (en) | 2003-08-01 | 2012-11-13 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
DE602004014937D1 (de) | 2003-08-01 | 2008-08-21 | Chugai Pharmaceutical Co Ltd | Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer |
JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
CN103275070A (zh) * | 2013-05-10 | 2013-09-04 | 郑彪 | 调节单核细胞增殖的四环化合物及其应用 |
US9427441B2 (en) | 2014-02-19 | 2016-08-30 | Indiana University Research And Technology Corporation | Targeting primary cilia to treat glaucoma |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005336A1 (en) * | 1996-08-08 | 1998-02-12 | Smithkline Beecham Corporation | Inhibitors of cysteine protease |
WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
WO2002017924A1 (en) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Method of treatment |
WO2002092563A2 (en) * | 2001-05-17 | 2002-11-21 | Smithkline Beecham Corporation | Protease inhibitors |
WO2003053331A2 (en) * | 2000-11-22 | 2003-07-03 | Smithkline Beecham Corporation | Protease inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69939752D1 (de) * | 1998-12-23 | 2008-11-27 | Smithkline Beecham Corp | 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors |
-
2001
- 2001-06-14 NZ NZ522965A patent/NZ522965A/en unknown
- 2001-06-14 CA CA002412353A patent/CA2412353A1/en not_active Abandoned
- 2001-06-14 AR ARP010102840A patent/AR032622A1/es not_active Application Discontinuation
- 2001-06-14 PE PE2001000566A patent/PE20011374A1/es not_active Application Discontinuation
- 2001-06-14 WO PCT/US2001/019062 patent/WO2001095911A1/en active IP Right Grant
- 2001-06-14 HU HU0301231A patent/HUP0301231A2/hu unknown
- 2001-06-14 SK SK1759-2002A patent/SK17592002A3/sk not_active Application Discontinuation
- 2001-06-14 CZ CZ20024086A patent/CZ20024086A3/cs unknown
- 2001-06-14 AP APAP/P/2002/002671A patent/AP2002002671A0/en unknown
- 2001-06-14 IL IL15342101A patent/IL153421A0/xx unknown
- 2001-06-14 AU AU2001268407A patent/AU2001268407A1/en not_active Abandoned
- 2001-06-14 MX MXPA02012442A patent/MXPA02012442A/es unknown
- 2001-06-14 PL PL36050801A patent/PL360508A1/xx not_active Application Discontinuation
- 2001-06-14 CN CN01813500A patent/CN1444481A/zh active Pending
- 2001-06-14 BR BR0111693-2A patent/BR0111693A/pt not_active IP Right Cessation
- 2001-06-14 JP JP2002510089A patent/JP2004503502A/ja active Pending
- 2001-06-14 OA OA1200200377A patent/OA12288A/en unknown
- 2001-06-14 EA EA200300018A patent/EA200300018A1/ru unknown
- 2001-06-14 EP EP01946344A patent/EP1307204A4/en not_active Withdrawn
- 2001-06-14 KR KR1020027017045A patent/KR20030008220A/ko not_active Application Discontinuation
-
2002
- 2002-11-28 BG BG107327A patent/BG107327A/bg unknown
- 2002-12-02 NO NO20025786A patent/NO20025786L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209808A patent/ZA200209808B/en unknown
- 2002-12-12 EC EC2002004388A patent/ECSP024388A/es unknown
- 2002-12-13 MA MA26952A patent/MA25758A1/fr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005336A1 (en) * | 1996-08-08 | 1998-02-12 | Smithkline Beecham Corporation | Inhibitors of cysteine protease |
WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
WO2002017924A1 (en) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Method of treatment |
WO2003053331A2 (en) * | 2000-11-22 | 2003-07-03 | Smithkline Beecham Corporation | Protease inhibitors |
WO2002092563A2 (en) * | 2001-05-17 | 2002-11-21 | Smithkline Beecham Corporation | Protease inhibitors |
Non-Patent Citations (2)
Title |
---|
See also references of WO0195911A1 * |
VEBER, DANIEL F. ET AL: "The role of conformational constraint in improved oral bioavailability of cathepsin K inhibitors", PEPTIDES 2000, PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, 26TH, MONTPELLIER, FRANCE, SEPT. 10-15, 2000 ( 2001 ), MEETING DATE 2000, 113-114. EDITOR(S): MARTINEZ, JEAN;FEHRENTZ, JEAN-ALAIN. PUBLISHER: EDITIONS EDK, PARIS, FR., XP009028910 * |
Also Published As
Publication number | Publication date |
---|---|
BG107327A (bg) | 2003-07-31 |
KR20030008220A (ko) | 2003-01-24 |
SK17592002A3 (sk) | 2003-05-02 |
ZA200209808B (en) | 2004-07-09 |
JP2004503502A (ja) | 2004-02-05 |
MA25758A1 (fr) | 2003-04-01 |
PL360508A1 (en) | 2004-09-06 |
AR032622A1 (es) | 2003-11-19 |
WO2001095911A1 (en) | 2001-12-20 |
NO20025786D0 (no) | 2002-12-02 |
HUP0301231A2 (hu) | 2003-08-28 |
NO20025786L (no) | 2003-02-12 |
CZ20024086A3 (cs) | 2003-05-14 |
CN1444481A (zh) | 2003-09-24 |
IL153421A0 (en) | 2003-07-06 |
AU2001268407A1 (en) | 2001-12-24 |
MXPA02012442A (es) | 2003-04-25 |
EA200300018A1 (ru) | 2003-06-26 |
PE20011374A1 (es) | 2002-04-07 |
CA2412353A1 (en) | 2001-12-20 |
EP1307204A1 (en) | 2003-05-07 |
AP2002002671A0 (en) | 2002-12-31 |
NZ522965A (en) | 2004-06-25 |
ECSP024388A (es) | 2003-02-06 |
BR0111693A (pt) | 2004-04-06 |
OA12288A (en) | 2003-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL150964A0 (en) | Protease inhibitors | |
TWI319763B (en) | Peptidomimetic protease inhibitors | |
GB0125445D0 (en) | Protease Inhibitors | |
IL153421A0 (en) | Protease inhibitors | |
EP1235577A4 (en) | PROTEASE INHIBITORS | |
EP1232155A4 (en) | PROTEASE INHIBITORS | |
IL151087A0 (en) | Protease inhibitors | |
EP1229912A4 (en) | PROTEASE INHIBITORS | |
EP1231921A4 (en) | PROTEASE INHIBITORS | |
EP1229915A4 (en) | PROTEASE INHIBITORS | |
EP1229914A4 (en) | PROTEASE INHIBITORS | |
EP1161237A4 (en) | PROTEASE INHIBITORS | |
EP1233771A4 (en) | PROTEASE INHIBITORS | |
EP1173429A4 (en) | PROTEASE INHIBITORS | |
EP1351930A4 (en) | PROTEASE INHIBITORS | |
EP1229911A4 (en) | PROTEASE INHIBITORS | |
EP1401453A4 (en) | PROTEASE INHIBITORS | |
EP1231923A4 (en) | PROTEASE INHIBITORS | |
HUP0301964A3 (en) | Protease inhibitors | |
IL155961A0 (en) | Cysteine protease inhibitors | |
EP1231922A4 (en) | PROTEASE INHIBITORS | |
EP1232154A4 (en) | PROTEASE INHIBITORS | |
AU6407701A (en) | Serine protease inhibitors | |
GB0009123D0 (en) | Protease inhibitor | |
ZA200207478B (en) | Protease inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030114 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040420 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 19/00 B Ipc: 7A 61P 35/04 B Ipc: 7A 61P 33/00 B Ipc: 7A 61P 31/00 B Ipc: 7A 61P 29/00 B Ipc: 7C 07D 417/14 B Ipc: 7C 07D 471/04 B Ipc: 7C 07D 409/14 B Ipc: 7C 07D 403/12 B Ipc: 7C 07D 401/14 B Ipc: 7C 07D 401/10 B Ipc: 7C 07D 405/14 B Ipc: 7C 07D 401/12 B Ipc: 7C 07D 409/12 B Ipc: 7C 07D 405/12 B Ipc: 7A 61K 31/55 A |
|
17Q | First examination report despatched |
Effective date: 20060810 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090630 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1057327 Country of ref document: HK |